Probiotics Clostridium butyricum and Bacillus subtilis ameliorate intestinal tumorigenesis.
OBJECTIVE
To investigate the antitumor effects of probiotics Clostridium butyricum and Bacillus subtilis on colorectal cancer (CRC) progression.


METHODS
The effects of C. butyricum and B. subtilis on CRC cells were studied. Male C57BL/6 mice with 1,2-dimethylhydrazine dihydrochloride (DMH)-induced CRC were intervened by these two probiotics and the antitumor effects were examined by comparing the tumor incidence and detecting the inflammatory and immune-related markers.


CONCLUSIONS
C. butyricum and B. subtilis inhibited the proliferation of CRC cells, caused cell cycle arrest and promoted apoptosis. In vivo, these two probiotics inhibited the development of DMH-induced CRC. The molecular mechanism involved reduced inflammation and improved immune homeostasis. This work establishes a basis for the protective role of probiotics B. subtilis and C. butyricum in intestinal tumorigenesis.
Division of Gastroenterology & Hepatology, Renji Hospital, School of Medicine, Shanghai Jiaotong University; Shanghai Institute of Digestive Disease, 145 Middle Shandong Road, Shanghai 200001, China.
Zhao-Fei
ZF
Chen
Division of Gastroenterology & Hepatology, Renji Hospital, School of Medicine, Shanghai Jiaotong University; Shanghai Institute of Digestive Disease, 145 Middle Shandong Road, Shanghai 200001, China.
Luo-Yan
LY
Ai
Division of Gastroenterology & Hepatology, Renji Hospital, School of Medicine, Shanghai Jiaotong University; Shanghai Institute of Digestive Disease, 145 Middle Shandong Road, Shanghai 200001, China.
Ji-Lin
JL
Wang
Division of Gastroenterology & Hepatology, Renji Hospital, School of Medicine, Shanghai Jiaotong University; Shanghai Institute of Digestive Disease, 145 Middle Shandong Road, Shanghai 200001, China.
Lin-Lin
LL
Ren
Division of Gastroenterology & Hepatology, Renji Hospital, School of Medicine, Shanghai Jiaotong University; Shanghai Institute of Digestive Disease, 145 Middle Shandong Road, Shanghai 200001, China.
Ya-Nan
YN
Yu
Division of Gastroenterology & Hepatology, Renji Hospital, School of Medicine, Shanghai Jiaotong University; Shanghai Institute of Digestive Disease, 145 Middle Shandong Road, Shanghai 200001, China.
Jie
J
Xu
Division of Gastroenterology & Hepatology, Renji Hospital, School of Medicine, Shanghai Jiaotong University; Shanghai Institute of Digestive Disease, 145 Middle Shandong Road, Shanghai 200001, China.
Hao-Yan
HY
Chen
Department of Medicine & Therapeutics, Institute of Digestive Disease & LKS Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong.
Jun
J
Yu
Department of Clinical Laboratory, Renji Hospital, School of Medicine, Shanghai Jiaotong University, China.
Min
M
Li
State Key Laboratory of Oncogenes & Related Genes, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiaotong University Shanghai, China.
Wen-Xin
WX
Qin
Division of Gastroenterology & Hepatology, Renji Hospital, School of Medicine, Shanghai Jiaotong University; Shanghai Institute of Digestive Disease, 145 Middle Shandong Road, Shanghai 200001, China.
Xiong
X
Ma
Division of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, China.
Nan
N
Shen
Division of Gastroenterology & Hepatology, Renji Hospital, School of Medicine, Shanghai Jiaotong University; Shanghai Institute of Digestive Disease, 145 Middle Shandong Road, Shanghai 200001, China.
Ying-Xuan
YX
Chen
Division of Gastroenterology & Hepatology, Renji Hospital, School of Medicine, Shanghai Jiaotong University; Shanghai Institute of Digestive Disease, 145 Middle Shandong Road, Shanghai 200001, China.
Jie
J
Hong
Division of Gastroenterology & Hepatology, Renji Hospital, School of Medicine, Shanghai Jiaotong University; Shanghai Institute of Digestive Disease, 145 Middle Shandong Road, Shanghai 200001, China.
Jing-Yuan
JY
Fang
D019813:1,2-Dimethylhydrazine; D000284:Administration, Oral; D000818:Animals; D017209:Apoptosis; D001412:Bacillus subtilis / Q000502:physiology*; D063646:Carcinogenesis; D059447:Cell Cycle Checkpoints; D045744:Cell Line, Tumor; D046972:Clostridium butyricum / Q000502:physiology*; D015179:Colorectal Neoplasms / Q000139:chemically induced / Q000517:prevention & control*; D017077:Culture Media, Conditioned; D018450:Disease Progression; D006706:Homeostasis; D007249:Inflammation / Q000628:therapy; D008297:Male; D008810:Mice, Inbred C57BL; D019936:Probiotics
D017077:Culture Media, Conditioned; D019813:1,2-Dimethylhydrazine
colorectal cancer; gut microbiota; immunity; inflammation